| 摘要 |
Disclosed are ([3-azabicyclo[3.1.0]hex-3-yl]alkoxy)benzamide derivatives as represented by the general formula (I), wherein: ALK represents an alkylene chain; W represents a group selected from -N(R')C(=O)-R and -C(=O)N(R')-R; wherein R and R' represent, each independently of the other, a hydrogen or a linear or branched alkyl group optionally substituted by one or more groups selected from halogen, hydroxy and alkoxy. Of particular importance are the compounds N-(4-{3-[(1R,5S)-3-azabicyclo[3.1.0]hex-3-yl]propoxy}phenyl)-N-methylacetamide, N-(4-{2-[(1R,5S)-3-azabicyclo[3.1.0]hex-3-yl]ethoxy}phenyl)acetamide, N-(4-{2-[(1R,5S)-3-azabicyclo[3.1.0]hex-3-yl]ethoxy}phenyl)-2-methoxyacetamide, 4-{3-[(1R,5S)-3-azabicyclo[3.1.0]hex-3-yl]propoxy}benzamide, 4-{2-[(1R,5S)-3-azabicyclo[3.1.0]hex-3-yl]ethoxy}benzamide, N-(4-{3-[(1R,5S)-3-azabicyclo[3.1.0]hex-3-yl]propoxy}phenyl)-2-methoxy-acetamide and N-(4-{3-[(1R,5S)-3-azabicyclo[3.1.0]hex-3-yl]propoxy}phenyl)acetamide. Also disclosed are pharmaceutical compositions which comprise at least one compound as defined above, optionally in combination with one or more pharmaceutically acceptable excipients, for use in the treatment of cognitive and psycho-behavioural disorders associated with cerebral ageing, with neurodegenerative diseases or with cranial traumas and also in the treatment of mood disorders, of schizophrenia and of cognitive disorders associated therewith, of sleep disorders, of sleep-waking rhythm disorders, of attention-deficit hyperactivity syndrome or obesity.
|
